05 Apr
Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference
WATERTOWN, Mass. , April 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
11 Mar
Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
-   First-in-human dose-escalation study to evaluate ability of ImmTOR™  to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 - -   Methylmalonic acidemia   (MMA) gene therapy program in collaboration with AskBio expected to enter the clinic in
04 Mar
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
WATERTOWN, Mass. , March 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to
01 Mar
Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference
WATERTOWN, Mass. , March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
24 Feb
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy
- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector - - ImmTOR shown to increase hepatic vector copy numbers and transgene mRNA expression - - Replicated findings supporting ImmTOR’s ability to block the formation of
17 Feb
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy – WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc.
16 Feb
Selecta Biosciences to Present at the SVB Leerink 10th Annual Global Healthcare Conference
WATERTOWN, Mass. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences , Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
06 Jan
Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTOR™ Platform in Gene Therapy
- Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigating the formation of neutralizing antibodies, compared to AAV8 alone – - Data support rapid advancement of Selecta’s gene therapy pipeline, including lead
04 Jan
Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference
WATERTOWN, Mass. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief